{
    "root": "3530bfab-9b2c-7fd0-e063-6394a90a6b1d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TREMFYA",
    "value": "20250515",
    "ingredients": [
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "GUSELKUMAB",
            "code": "089658A12D"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        }
    ],
    "indications": "TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 )",
    "contraindications": "For the treatment of Crohn’s disease or ulcerative colitis: Obtain liver enzymes and bilirubin levels prior to initiating treatment with TREMFYA ( 2.1 , 5.4 ). Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to treatment initiation. ( 2.1 ) Recommended Dosage Plaque Psoriasis 100 mg administered by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. ( 2.2 ) Psoriatic Arthritis 100 mg administered by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. TREMFYA can be used alone or in combination with a conventional DMARD (e.g., methotrexate). ( 2.3 ) Ulcerative Colitis Induction : 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. ( 2.4 ) Maintenance : 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic response. ( 2.4 ) Crohn's Disease Induction : 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8 or 400 mg administered by subcutaneous injection at Week 0, Week 4, and Week 8. Maintenance : 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic response. ( 2.5 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "TREMFYA is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients\n \n  [see\n  \n   Warnings and Precautions (5.1)]\n \n  ."
}